We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Novel Therapeutic Solution for Aortic Aneurysms

By HospiMedica International staff writers
Posted on 14 Jun 2016
An innovative solution facilitates the endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA) in patients with challenging anatomies.

The Gore Excluder Conformable AAA endoprosthesis is made of expanded polytetrafluoroethylene (ePTFE) graft material and a nitinol stent, and relies on an active control system (ACS) which allows physicians to angle the device for optimal conformability and maximal seal in the proximal aortic neck. More...
The Excluder is characterized by its low profile, flexible on and off catheter characteristics, and active infrarenal fixation, which provides the physician with a proven and durable option to better treat a broader range of patients diagnosed with abdominal aortic aneurysms.

Other features include proprietary low profile sleeve technology, a repositionable delivery system, and a simple three-stage deployment procedure. The Gore Excluder Conformable AAA endoprosthesis is a product of Gore Medical Products (Flagstaff, AZ, USA), and is intended for patients with proximal aortic neck angles of up to 90 degrees with a minimum aortic neck length of 15 mm, and in patients with proximal aortic neck angles of up to 60 degrees with a minimum aortic neck length of 10 mm.

“In order to qualify for EVAR, the patient had to fit a fairly narrow subset of anatomical criteria,” said Robert Rhee, MD, chief of vascular and endovascular surgery at Maimonides Medical Center (New York, NY, USA). “The Gore Excluder Conformable AAA endoprosthesis will expand the applicability of EVAR to patients traditionally considered to have anatomy too challenging for endovascular treatment.”

“With the Gore Excluder conformable device, our EVAR solutions will offer the broadest treatment range of any supplier in the market,” said Ryan Takeuchi, aortic business unit leader at Gore. “The feedback received on this new product suggests a high level of interest from physicians seeking to treat challenging AAA anatomies. As we scale up operations to meet this demand, we look forward to bringing this valuable product to patients and physicians.”

AAA is the localized dilatation of the abdominal aorta exceeding the normal diameter by more than 50%, and is the most common form of aortic aneurysm; approximately 90% occur below the kidneys. The aneurysms can extend to include one or both of the pelvic iliac arteries. The major complication of AAA is rupture, which is life-threatening, as large amounts of blood spill into the abdominal cavity, and can lead to death within minutes. Mortality during rupture repair in the hospital is 60-90%.

Related Links:
Gore Medical Products


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.